The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Krka Tovarna Zdravil competitive analysis

Loading summary...

Latest patents of Krka Tovarna Zdravil opposed by its competitors

Explore Krka Tovarna Zdravil's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2588090
Nov 22, 2023Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable Salts3
EP2585051
Apr 8, 2020Pharmaceutical Oral Dosage Forms Comprising Lercanidipine And Enalapril And Their Pharmaceutically Acceptable Salts1

Latest PTAB cases involving Krka Tovarna Zdravil

Discover the latest PTAB cases involving Krka Tovarna Zdravil, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Krka Tovarna Zdravil with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
KRKA TOVARNA ZDRAVIL - 4 - -
EDER3 - - -
GENERICS UK214 - - -
GEORG KALHAMMERSTEPHAN TEIPEL3 - - -